About US
Contact us
-
J&J fails latest bid to 'cut and run' from Oklahoma opioid trial: AGAfter prosecutors rested their case in the Oklahoma opioid lawsuit, Johnson & Johnson kicked up an argument to toss out the case altogether. The state didn't offer enough evidence to show J&2019/7/8
-
Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analystIt’s not uncommon for drugmakers to raise prices on big-selling meds to start each year and at each year's halfway point. So as the calendar turned to July, many companies marked the occasion with2019/7/5
-
Sanofi, Eisai join Lilly's SCOTUS bid to save Cialis from 'overly broad' patent claimsEli Lilly has a message for the U.S. Supreme Court: We aren’t going to take a $20 million patent loss for Cialis sitting down. Now, Lilly can count on a couple of friends ready to join the fight—and2019/7/5
-
Roche pushes back Spark merger deadline as U.S., U.K. antitrust reviews drag onRoche and Spark Therapeutics’ road to a $4.3 billion merger has been a rocky one, with various delays pushing the long-gestating agreement back four times. Now, in order to get all its regulatory duc2019/7/4
-
NICE shuts down AZ's Tagrisso—and backs Pfizer rival Vizimpro insteadEngland’s cost watchdogs won’t get behind AstraZeneca blockbuster Tagrisso in previously untreated patients with EGFR-mutated lung cancer. But in a change of events, they’re instead backing a Pfizer2019/7/4
-
Merck abandons $7M in grants for long-term IT hiring plan in AustinWhen Merck moseyed into the Lone Star State as part of a global IT restructuring, it pitched a robust hiring plan in exchange for nearly $7 million in tax breaks and grants. Now, after Merck pulled b2019/7/3
-
Post-Shire buy, Takeda investors want executives to return pay if performance lagsTakeda wrapped up its $60 billion Shire takeoverearly this year with massive support from shareholders, despite previous resistance. But the weight on the deal's mastermind, Takeda CEO Christophe W2019/7/3
-
Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analystsOnly about one-third of the top 30 U.S. insurance companies have made their decisions about how to cover Novartis’ new $2.1 million gene therapy to treat spinal muscular atrophy (SMA), Zolgensma, but2019/7/2
-
Warren blasts Gottlieb's jump to Pfizer, but ex-FDA chief says he's 'proud'Scott Gottlieb and Pfizer surely knew critics would challenge the former FDA commissioner’s decision to join the pharma giant's board—less than three months after his departure from the agency, no le2019/7/2
-
Sanofi, Regeneron's Libtayo hits hot streak with EU green light, NICE backingSanofi and Regeneron’s Libtayo is two for two in the last two days—with European officials, that is. One day after the European Commissionclearedthe PD-1 drug to treat cutaneous squamous cell carcino2019/7/1